Cryptosporidium parvum is an ubiquitous protozoan parasite that is a major cause of diarrhoea in individuals infected with human immunodeficiency virus. The halhmarks of infection include profuse watery diarrhoea which may become chronic in the severely inmunosuppressed individual. No uniformly effective therapy exists. Current treatment relies upon a trial of anti-retroviral and specific anti-cryptosporidial medications, adequate fluid and nutritional support, and antimotility agents.
Cryptosporidium parvum is a coccidian protozoan parasite that belongs to the same family as Isospora and Toxoplasma.' Since its discovery by Tyzer in 1907 and until the advent of autoimmune deficiency syndrome (AIDS), Cryptosporidium was primarily regarded as a cause of diarrhoea among animals. 2 Indeed, before 1982, only seven cases of human cryptosporidiosis had been reported in the medical literature. The last 15 years has witnessed a dramatic increase in the number of cases, owing to better diagnostic methods and a growing population of individuals infected with human immunodeficiency virus (HIV).3
Aetiology
Symptoms of cryptosporidial infection begin 5 -22 days after ingestion of as few as 30 oocysts of human, animal or environmental origin.4 After ingestion, oocysts excyst and release sporozoites, the infective form of the parasite. The sporozoites implant on the mucosal surface of host epithelial cells and undergo sexual and asexual reproduction with generation of oocysts and merozoites, respectively. Merozoites continue the process of mucosal auto-infection while oocysts are immediately infectious and are excreted in stools. Note that the entire life-cycle takes place within a single host." 2 Though the most common site of infection is the gut, extra-intestinal infection has been reported rarely, most commonly in the respiratory tract. 5 The precise mechanism by which Cryptosporidium causes diarrhoea is unknown. Ultrastructural studies reveal that, while the parasite attaches to the mucosal epithelial lining, it does not invade the submucosa. 6 Mechanisms that promote clearance of C parvum remain unclear. On the basis of clinical and experimental data, it is generally accepted that both the humoral and cellular immune systems are required for control of infection.7 Studies using several animal models suggest that loss of T-lymphocyte function may lead to persistent cryptosporidiosis.8 The importance of B-cell-mediated immunity is suggested by the fact that immunocompromised persons with hypo-gammaglobulinaemia or isolated IgA deficiency may develop chronic cryptosporidiosis.9"lo Epidemiology Cryptosporidium is an ubiquitous parasite and infections have been traced to household or sick contacts, agricultural exposure, and contaminated water and food. The ease with which humans become infected is illustrated by attack rates of up to 70% in adult contacts of infected children in day-care centres.2 Widespread previous exposure or infection has been documented by several sero-epidemiological surveys revealing high prevalence of specific anticryptosporidial IgG in all paediatric and adult populations studied thus far." "2 Attempts to control environmental sources of infection have been thwarted by the resilient oocysts which can withstand extremes of temperature as well as standard disinfectants and chlorine. Particularly worrisome is the inability of water purification systems to eliminate Cryptosporidium.""3 4 The oocyst is only 4 jym in diameter, making it difficult to clear through filtration.' Communitywide outbreaks, such as the one in Milwaukee, US, which affected more than 400 000 people, have been traced to the public water supply. '5 Clinical manifestations Acute infection is characterised by watery diarrhoea with 6 -12 bowel movements/day, crampy epigastric pain, weight loss, anorexia, malaise and flatulence. Such symptoms are typical of diseases of the small bowel, the primary site of cryptosporidial infection. Nausea, vomiting and fever may also be present. A small subset of patients may present with colitis but primary Cryptosporidiosis is diagnosed by identifying oocysts in stool or gastrointestinal biopsy specimens. Though many stool identification techniques exist, the most widely used method is the acid-fast stain (cold Kinyoun modified, hot Kinyoun, Ziehl-Neelsen).' Oocysts stain red with varying intensity allowing differentiation from similarly sized and shaped yeast which are not acid fast. Other studies, such as the direct immunofluorescent assay which utilises a monoclonal antibody, may increase the sensitivity of stool identification. If initial studies are negative, the optimum number of stool specimens for diagnosis is unknown. Serial stool specimens in HIV-infected persons reveal 10-fold variation in cryptosporidial oocyst shedding.2' The importance of obtaining multiple specimens (eg, at least three specimens on three separate days) is supported by studies on other protozoa that demonstrate increased yield with additional stool samples. 22 If stool studies are negative, endoscopy should be considered to establish a definitive diagnosis when diarrhoea is refractory to antimotility agents or when the disease process changes (eg, development of colitic symptoms, bloody diarrhoea, right upper quadrant pain). Endoscopic biopsy specimens may reveal Cryptosporidium when stool studies have been negative in <10% of patients. Other pathogens such as cytomegalovirus or Microsporidia may also be identified.'8 When examining intestinal biopsy material, Cryptosporidia can be identified on the brush border of the mucosal epithelial surface and appear basophilic with haematoxylin and eosin staining. Failure to identify Cryptosporidia in intestinal biopsy material does not rule out diagnosis, as cryptosporidial distribution may be patchy.23 Other identification methods include concentration techniques such as Sheather's sugar flotation.
Treatment NUTRITIONAL AND FLUID SUPPORT
Cryptosporidial diarrhoea is voluminous and individuals may lose up to 17 1/day in stool.24 Fluid loss is especially prominent in debilitated individuals who are unable to drink. Utmost attention needs to be paid to correction of electrolyte abnormalities and prevent dehydration with intravenous or oral rehydration solutions (ORS). A simple home-made ORS is 200 ml of water with an eighth of a teaspoon of salt and two teaspoons of sugar. Individuals should be encouraged to start ORS early to prevent even initial dehydration.
Optimum nutritional support should include a trial of oral nutritional supplements before considering total parenteral or intravenous hyperalimentation. Nutritional supplements containing medium chain fatty acids may be better absorbed in patients with small intestinal injury and malabsorption. Milk and dairy products should be avoided since lactose intolerance is common. Another therapeutic approach has been the use of immune-based therapies such as hyperimmune bovine colostrum and bovine transfer factor. These agents are produced by inoculating cows with cryptosporidial oocysts and isolating specific anticryptosporidial antibody or transfer factor from the cows' milk or lymph nodes, respectively. Trials have been limited by small numbers of patients, cumbersome production techniques and difficulty in standardising different batches of product.26'27 ANTIRETROVIRAL AGENTS Although resolution of cryptosporidial infection with zidovudine has been documented in case report format, no studies have shown a definitive benefit of therapy in cryptosporidiosis.28 At present, combination antiretroviral therapy including protease inhibitors is recommended by the authors in the hope that the ensuing boost in immune function will help combat cryptosporidial infection.
ANTIMOTILITY AGENTS Antimotility agents should be used for symptomatic relief and include first-line agents such as loperamide and diphenoxylate/atropine (lomotil). A stronger agent, tincture of opium, can be used for refractory diarrhoea with the warning that over-use may lead to hypomotility, constipation and nausea. Antimotility agents should be stopped immediately if bloody diarrhoea or fever develops and should not be restarted until the presence of invasive organisms has been ruled out. Trials of other antimotility agents such as octreotide, a somatostatin analogue, have not shown them to be more effective than standard agents in controlling diarrhoeal symptoms.29
Conclusions
Cryptosporidium is one of multiple emerging pathogens that poses considerable challenges to medical science. As populations of immunocompromised p sons grow, it will cause increasing morbidity due to chronic severe enteritis. Innovative methods to treat this infection are urgently needed. Immunotherapeutic trials with orally administered Cryptosporidium polyclonal or monoclonal antibodies are ongoing. Novel pharmacologic approaches based on a better understanding of the biology of this protozoa may be effective. A successful vaccine to induce mucosal immunity would be a great advance. 
